Ascletis Pharma (HKG:1672) will present data from its 28-day multiple ascending dose study of ASC30 in an oral discussion at the 61st European Association for the Study of Diabetes Annual Meeting in Vienna, Austria, a Tuesday Hong Kong bourse filing said.
The drug demonstrated superior weight loss in participants with obesity in the relevant study.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.